A specific fluorescence resonance energy quenching–based biosensor for measuring thrombin activity in whole blood
At sites of vessel injury, thrombin acts as the central mediator of coagulation by catalyzing fibrin clot formation and platelet activation. Thrombin generation is most frequently measured in plasma samples using small-molecule substrates; however, these have low specificity for thrombin and limited...
Saved in:
Published in | Journal of thrombosis and haemostasis Vol. 22; no. 6; pp. 1627 - 1639 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Inc
01.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | At sites of vessel injury, thrombin acts as the central mediator of coagulation by catalyzing fibrin clot formation and platelet activation. Thrombin generation is most frequently measured in plasma samples using small-molecule substrates; however, these have low specificity for thrombin and limited utility in whole blood. Plasma assays are limited because they ignore the hemostatic contributions of blood cells and require anticoagulation and the addition of supraphysiological concentrations of calcium.
To overcome these limitations, we designed and characterized a fluorescence resonance energy quenching–based thrombin sensor (FTS) protein.
The fluorescence resonance energy quenching pair of mAmetrine and tTomato, separated by a thrombin recognition sequence, was developed. The protein was expressed using Escherichia coli, and purity was assessed using sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The cleavage of FTS was monitored by fluorescence using excitation at 406 nm and emission at 526 nm and 581 nm.
Compared with small-molecule substrates, the FTS demonstrated high specificity for thrombin; it is not cleaved by thrombin or inhibited by α2-macroglobulin and interacts with thrombin’s anion-binding exosite I. The FTS can effectively measure thrombin generation in plasma and in finger-prick whole blood, which allows it to be developed into a point-of-care test of thrombin generation. The FTS does not inhibit standard thrombin-generation assays. Lastly, FTS-based thrombin generation in nonanticoagulated finger-prick blood was delayed but enhanced compared with that in citrated plasma.
The FTS will broaden our understanding of thrombin generation in ways that are not attainable with current methods. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1538-7836 1538-7836 |
DOI: | 10.1016/j.jtha.2024.02.007 |